The Democratic Republic of Congo (DRC) faces another major Ebola outbreak, this time caused by the Bundibugyo type of the virus genus Orthoebolavirus. First identified in Uganda in 2007 and later in the DRC in 2012, the Bundibugyo strain has infected thousands of people, yet there is still no officially licensed vaccine or treatment specifically targeting it.
Medical experts point to missed opportunities to develop vaccines during previous outbreaks. Torsten Feldt, a tropical medicine doctor at Düsseldorf’s University Hospital, noted that scientists had sufficient time since earlier Bundibugyo epidemics to develop vaccines, but promising chances were not seized, leading to lost crucial time during the current outbreak.
Scientific Potential and Vaccine Limitations
From an immunological viewpoint, Ebola viruses—unlike rapidly mutating influenza or evasive HIV—are considered good candidates for vaccine development due to their relative predictability. Leonie Mayer from the German Center for Infection Research emphasized that while vaccines such as Ervebo have been licensed against the Zaire Ebola variant, their effectiveness against other types like Bundibugyo remains unproven and can only be assessed during actual outbreaks.
Mayer’s recent study found that Ervebo does trigger cross-reactive T-cell responses against the Bundibugyo virus, suggesting the immune system can recognize this strain. However, it remains unclear if this immune response translates into actual protection or milder disease progression. Ethically, deploying a vaccine without confirmed efficacy poses risks, including false security, loss of trust, and impaired ability to conduct controlled studies.
Complexities in Containment and Vaccine Development
The Bundibugyo virus is considered less aggressive than the Zaire variant, potentially complicating containment as infected individuals remain mobile longer and may unknowingly spread the virus. Moreover, the lack of vaccines specific to this strain limits response efforts, and logistical challenges such as conflict zones and difficult transportation hinder rapid diagnosis and intervention.
Specimens often require long-distance transportation from remote areas to laboratories, slowing outbreak responses even as detection methods improve. The key bottleneck is the speed and effectiveness of action following case identification.
Looking Ahead: Vaccine Trials and Long-Term Goals
New vaccine trials, including those evaluating Ervebo and a Moderna mRNA vaccine in the DRC’s Tumaini study, aim to provide clearer data on efficacy against Bundibugyo. However, experts estimate widespread availability of an effective Bundibugyo vaccine is unlikely before mid-2027.
Long-term efforts focus on developing cross-reactive pan-Ebola vaccines capable of protecting against multiple Ebola virus types. Until then, the priority remains advancing targeted vaccines for currently circulating strains like Bundibugyo amidst ongoing outbreak challenges.
